PDL Biopharma (PDLI) 8-K Regulation FD Disclosure

Exhibit 99.2

Royalty Revenue by Product ($ in 000's) *
Avastin	Q1		Q2		Q3		Q4		Total
2013		33,234		46,720		32,224		-		112,177
2012		23,215		41,670		25,955		30,041		120,882
2011		22,283		41,967		23,870		22,886		111,006
2010		16,870		44,765		29,989		24,922		116,547
2009		13,605		35,161		21,060		15,141		84,966
2008		9,957		30,480		19,574		12,394		72,405
2007		8,990		21,842		17,478		9,549		57,859
2006		10,438		15,572		15,405		12,536		53,952
Herceptin	Q1		Q2		Q3		Q4		Total
2013		30,287		47,353		30,961		-		108,602
2012		25,702		44,628		30,433		28,307		129,070
2011		25,089		42,209		31,933		21,812		121,042
2010		23,402		38,555		27,952		25,441		115,350
2009		16,003		32,331		26,830		18,615		93,779
2008		14,092		34,383		28,122		20,282		96,880
2007		19,035		28,188		22,582		14,802		84,608
2006		15,142		19,716		21,557		20,354		76,769
Lucentis	Q1		Q2		Q3		Q4		Total
2013		12,032		30,066		13,536		-		55,633
2012		10,791		27,938		12,552		11,097		62,377
2011		8,878		24,313		12,157		10,750		56,099
2010		7,220		19,091		10,841		8,047		45,198
2009		4,621		12,863		8,123		6,152		31,759
2008		3,636		11,060		7,631		4,549		26,876
2007		2,931		6,543		6,579		3,517		19,570
2006		-		-		289		3,335		3,624
Xolair	Q1		Q2		Q3		Q4		Total
2013		5,930		10,025		7,334		-		23,288
2012		5,447		8,609		6,504		6,145		26,705
2011		4,590		7,621		5,916		5,823		23,949
2010		3,723		6,386		4,980		4,652		19,741
2009		2,665		5,082		4,085		3,722		15,553
2008		1,488		4,866		3,569		2,927		12,850
2007		1,684		3,942		3,332		2,184		11,142
2006		2,263		2,969		3,041		2,495		10,768
Perjeta	Q1		Q2		Q3		Q4		Total
2013		340		1,414		748		-		2,502
2012		-		-		58		250		308
2011		-		-		-		-		-
2010		-		-		-		-		-
2009		-		-		-		-		-
2008		-		-		-		-		-
2007		-		-		-		-		-
2006		-		-		-		-		-
Kadcyla	Q1		Q2		Q3		Q4		Total
2013		-		551		830		-		1,381
2012		-		-		-		-		-
2011		-		-		-		-		-
2010		-		-		-		-		-
2009		-		-		-		-		-
2008		-		-		-		-		-
2007		-		-		-		-		-
2006		-		-		-		-		-
Tysabri	Q1		Q2		Q3		Q4		Total
2013		12,965		13,616		11,622		-		38,203
2012		11,233		12,202		11,749		12,255		47,439
2011		9,891		10,796		11,588		11,450		43,725
2010		8,791		8,788		8,735		9,440		35,754
2009		6,656		7,050		7,642		8,564		29,912
2008		3,883		5,042		5,949		6,992		21,866
2007		839		1,611		2,084		2,836		7,370
2006		-		-		-		237		237
Actemra	Q1		Q2		Q3		Q4		Total
2013		2,631		2,816		2,939		-		8,386
2012		1,705		2,074		2,145		2,462		8,385
2011		913		1,136		1,401		1,460		4,910
2010		1,587		237		315		688		2,827
2009		585		537		909		1,197		3,228
2008		44		-		146		369		559
2007		32		-		-		17		49
2006		-		-		-		-		-

* As reported to PDL by its licensees

   Totals may not sum due to rounding

Reported Net Sales Revenue by Product ($ in 000's) *
Avastin	Q1		Q2		Q3		Q4		Total
2013		1,653,108		1,694,678		1,746,135		-		5,093,921
2012		1,502,757		1,573,727		1,551,327		1,662,977		6,290,788
2011		1,597,461		1,582,705		1,581,095		1,469,994		6,231,255
2010		1,506,788		1,596,892		1,594,707		1,646,218		6,344,605
2009		1,345,487		1,295,536		1,439,730		1,514,053		5,594,806
2008		980,715		1,084,930		1,180,427		1,239,382		4,485,454
2007		678,068		746,587		797,013		875,084		3,096,752
2006		439,318		516,052		570,551		592,897		2,118,817
Herceptin	Q1		Q2		Q3		Q4		Total
2013		1,681,574		1,744,145		1,681,860		-		5,107,579
2012		1,515,255		1,625,313		1,663,695		1,650,495		6,454,759
2011		1,391,568		1,559,975		1,642,898		1,432,771		6,027,211
2010		1,270,846		1,349,512		1,300,934		1,409,310		5,330,602
2009		1,210,268		1,133,993		1,226,435		1,278,626		4,849,323
2008		1,105,426		1,195,215		1,211,982		1,186,806		4,699,428
2007		891,761		949,556		979,602		1,015,033		3,835,952
2006		529,585		659,719		761,099		803,576		2,753,979
Lucentis	Q1		Q2		Q3		Q4		Total
2013		1,203,179		1,171,423		1,200,791		-		3,575,394
2012		1,079,092		1,086,543		1,097,541		1,109,695		4,372,871
2011		887,757		943,418		1,052,809		1,075,015		3,958,999
2010		721,967		698,890		745,376		804,684		2,970,917
2009		462,103		469,736		555,296		615,212		2,102,347
2008		363,615		393,682		460,167		454,922		1,672,386
2007		224,820		219,579		299,995		322,300		1,066,695
2006		-		-		10,689		157,742		168,431
Xolair	Q1		Q2		Q3		Q4		Total
2013		341,309		365,778		391,900		-		1,098,987
2012		310,234		314,638		347,796		340,431		1,313,100
2011		267,754		277,642		310,874		314,911		1,171,182
2010		228,859		225,878		251,055		263,389		969,179
2009		184,669		181,086		211,006		219,693		796,454
2008		137,875		169,521		177,179		183,753		668,329
2007		129,172		130,700		144,250		147,754		551,876
2006		95,241		99,354		112,608		118,002		425,204
Perjeta	Q1		Q2		Q3		Q4		Total
2013		34,008		55,076		66,353		-		155,437
2012		-		-		5,080		25,000		30,079
2011		-		-		-		-		-
2010		-		-		-		-		-
2009		-		-		-		-		-
2008		-		-		-		-		-
2007		-		-		-		-		-
2006		-		-		-		-		-
Kadcyla	Q1		Q2		Q3		Q4		Total
2013		-		21,459		73,626		-		95,085
2012		-		-		-		-		-
2011		-		-		-		-		-
2010		-		-		-		-		-
2009		-		-		-		-		-
2008		-		-		-		-		-
2007		-		-		-		-		-
2006		-		-		-		-		-
Tysabri	Q1		Q2		Q3		Q4		Total
2013		434,677		451,358		387,407		-		1,273,442
2012		374,430		401,743		391,623		408,711		1,576,508
2011		329,696		356,876		388,758		381,618		1,456,948
2010		293,047		287,925		293,664		316,657		1,191,292
2009		221,854		229,993		257,240		285,481		994,569
2008		129,430		163,076		200,783		233,070		726,359
2007		30,468		48,715		71,972		94,521		245,675
2006		-		-		-		7,890		7,890
Actemra	Q1		Q2		Q3		Q4		Total
2013		87,703		91,374		97,961		-		277,038
2012		56,662		66,624		71,505		82,053		276,843
2011		30,433		35,370		46,709		48,671		161,183
2010		52,908		5,405		10,493		22,919		91,725
2009		19,504		17,920		30,313		39,888		107,625
2008		1,452		1,377		5,981		12,305		21,115
2007		-		-		-		1,137		1,137
2006		-		-		-		-		-

* As reported to PDL by its licensee. Dates in above charts reflect when PDL receives royalties on sales. Sales occurred in the quarter prior to the dates in the above charts.

   Totals may not sum due to rounding

Manufacturing Location & Sales - Genentech / Roche & Novartis ($ in 000's) *

Avastin Sales	2012 - Q2			2012 - Q3			2012 - Q4			2013 - Q1			2013 - Q2			2013 - Q3
US Made & Sold		724,483			679,914			710,501			664,109			750,491			716,337
US Made & ex-US Sold		532,979			428,976			281,905			161,369			165,651			360,177
ex-US Made & Sold		316,265			442,437			670,572			827,629			778,536			669,621
Total		1,573,727			1,551,327			1,662,977			1,653,108			1,694,678			1,746,135
US Made & Sold		46	%		44	%		43	%		40	%		44	%		41	%
US Made & ex-US Sold		34	%		28	%		17	%		10	%		10	%		21	%
ex-US Made & Sold		20	%		29	%		40	%		50	%		46	%		38	%
Herceptin Sales	2012 - Q2			2012 - Q3			2012 - Q4			2013 - Q1			2013 - Q2			2013 - Q3
US Made & Sold		497,109			503,612			515,790			514,113			583,677			518,790
US Made & ex-US Sold		466,477			545,625			552,127			486,400			563,243			522,159
ex-US Made & Sold		661,727			614,459			582,578			681,060			597,225			640,911
Total		1,625,313			1,663,695			1,650,495			1,681,574			1,744,145			1,681,860
US Made & Sold		31	%		30	%		31	%		31	%		33	%		31	%
US Made & ex-US Sold		29	%		33	%		33	%		29	%		32	%		31	%
ex-US Made & Sold		41	%		37	%		35	%		41	%		34	%		38	%
Lucentis Sales	2012 - Q2			2012 - Q3			2012 - Q4			2013 - Q1			2013 - Q2			2013 - Q3
US Made & Sold		412,131			385,746			381,592			392,207			419,030			449,834
US Made & ex-US Sold		674,411			711,795			728,103			810,972			752,393			750,958
ex-US Made & Sold		-			-			-			-			-			-
Total		1,086,543			1,097,541			1,109,695			1,203,179			1,171,423			1,200,791
US Made & Sold		38	%		35	%		34	%		33	%		36	%		37	%
US Made & ex-US Sold		62	%		65	%		66	%		67	%		64	%		63	%
ex-US Made & Sold		0	%		0	%		0	%		0	%		0	%		0	%
Xolair Sales	2012 - Q2			2012 - Q3			2012 - Q4			2013 - Q1			2013 - Q2			2013 - Q3
US Made & Sold		193,600			211,702			210,892			207,976			218,860			236,180
US Made & ex-US Sold		-			-			-			-			-			-
ex-US Made & Sold		121,039			136,094			129,540			133,333			146,918			155,720
Total		314,638			347,796			340,431			341,309			365,778			391,900
US Made & Sold		62	%		61	%		62	%		61	%		60	%		60	%
US Made & ex-US Sold		0	%		0	%		0	%		0	%		0	%		0	%
ex-US Made & Sold		38	%		39	%		38	%		39	%		40	%		40	%
Perjeta Sales	2012 - Q2			2012 - Q3			2012 - Q4			2013 - Q1			2013 - Q2			2013 - Q3
US Made & Sold		-			5,080			24,571			32,377			48,979			49,111
US Made & ex-US Sold		-			-			428			1,632			6,096			17,242
ex-US Made & Sold		-			-			-			-			-			-
Total		-			5,080			25,000			34,008			55,076			66,353
US Made & Sold		0	%		100	%		98	%		95	%		89	%		74	%
US Made & ex-US Sold		0	%		0	%		2	%		5	%		11	%		26	%
ex-US Made & Sold		0	%		0	%		0	%		0	%		0	%		0	%
Kadcyla Sales	2012 - Q2			2012 - Q3			2012 - Q4			2013 - Q1			2013 - Q2			2013 - Q3
US Made & Sold		-			-			-			-			21,459			72,887
US Made & ex-US Sold		-			-			-			-			-			739
ex-US Made & Sold		-			-			-			-			-			-
Total		-			-			-			-			21,459			73,626
US Made & Sold		0	%		0	%		0	%		0	%		100	%		99	%
US Made & ex-US Sold		0	%		0	%		0	%		0	%		0	%		1	%
ex-US Made & Sold		0	%		0	%		0	%		0	%		0	%		0	%
Total Sales	2012 - Q2			2012 - Q3			2012 - Q4			2013 - Q1			2013 - Q2			2013 - Q3
US Made & Sold		1,827,323			1,786,053			1,843,345			1,810,783			2,042,496			2,043,139
US Made & ex-US Sold		1,673,867			1,686,395			1,562,564			1,460,373			1,487,383			1,651,276
ex-US Made & Sold		1,099,031			1,192,990			1,382,690			1,642,023			1,522,679			1,466,252
Total		4,600,221			4,665,438			4,788,598			4,913,178			5,052,559			5,160,667
US Made & Sold		40	%		38	%		38	%		37	%		40	%		40	%
US Made & ex-US Sold		36	%		36	%		33	%		30	%		29	%		32	%
ex-US Made & Sold		24	%		26	%		29	%		33	%		30	%		28	%

* As reported to PDL by its licensee. Dates in above charts reflect when PDL receives royalties on sales. Sales occurred in the quarter prior to the dates in the above charts.                                                

   Totals may not sum due to rounding